Meridian Bioscience, Inc.

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating Meridian (NASDAQ: VIVO) for possible breaches of fiduciary duty and other violations of law in its transaction with the Consortium.

Ademi LLP alleges Meridian’s financial outlook and prospects are excellent and yet Meridian holders will receive only $34.00 per share in an all-cash transaction valued at approximately $1.53 billion. The transaction agreement unreasonably limits competing bids for Meridian by imposing a significant penalty if Meridian accepts a superior bid. Meridian insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Meridian’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Meridian.